SCHEMBL6765858

SCHEMBL6765858

N#Cc1ccc(CN2Cc3cc(C(=O)O)ccc3C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HDAC1 Q13547 4/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
AR P10275 1/20 0.43
HPGD P15428 1/20 0.42
GRM5 P41594 1/20 0.42
ENPP2 Q13822 1/20 0.41
PTGER4 P35408 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
PRMT5 O14744 4/20 0.40
WDR77 Q9BQA1 4/20 0.40
HDAC7 Q8WUI4 1/20 0.40
PGR P06401 1/20 0.40
NR3C2 P08235 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169640 0.82 AR (0.42) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL6765103 0.81 MEN1 (0.46) MEN1KMT2AHDAC1HDAC6HPGD
SCHEMBL1002813 0.81 GRM5 (0.58) MEN1KMT2AHDAC1HDAC6GRM5
SCHEMBL7979501 0.81 L3MBTL1 (0.53) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL8347050 0.80 ROCK2 (0.49) HDAC1
SCHEMBL446687 0.79 SRD5A1 (0.49) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL23387571 0.78 POLB (0.55) MEN1KMT2AHPGDITGB3ITGA2B
SCHEMBL5012362 0.78 KMT2A (0.71) MEN1KMT2AHPGDENPP2
SCHEMBL14991856 0.76 PRMT5 (0.44) MEN1KMT2AGRM5PRMT5WDR77
SCHEMBL1065002 0.76 MEN1 (0.69) MEN1KMT2AHDAC1HDAC6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US claimed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US disclosed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis MMP13, MMP11, MMP9 MEN1 2463/4885KMT2A 4041/4885HDAC1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.